150 related articles for article (PubMed ID: 31092379)
1. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.
Martin E; Lamba N; Flucke UE; Verhoef C; Coert JH; Versleijen-Jonkers YMH; Desar IME
Crit Rev Oncol Hematol; 2019 Jun; 138():223-232. PubMed ID: 31092379
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
[TBL] [Abstract][Full Text] [Related]
4. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
[TBL] [Abstract][Full Text] [Related]
5. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
7. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
Hassan A; Pestana RC; Parkes A
Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
[TBL] [Abstract][Full Text] [Related]
8. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
9. Malignant Peripheral Nerve Sheath Tumors.
Durbin AD; Ki DH; He S; Look AT
Adv Exp Med Biol; 2016; 916():495-530. PubMed ID: 27165368
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
11. Current treatment options for malignant peripheral nerve sheath tumors.
Bradford D; Kim A
Curr Treat Options Oncol; 2015 Mar; 16(3):328. PubMed ID: 25777573
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Liao ZC; Zhang C; Liu XY; Ren ZW; Xu J; Zhang CZ; Yang Y; Zhu Z; Yang JL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):648-653. PubMed ID: 31550853
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
14. Management of childhood malignant peripheral nerve sheath tumor.
Ferrari A; Bisogno G; Carli M
Paediatr Drugs; 2007; 9(4):239-48. PubMed ID: 17705563
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review.
Martin E; Acem I; Grünhagen DJ; Bovée JVMG; Verhoef C
Front Oncol; 2020; 10():594069. PubMed ID: 33415076
[TBL] [Abstract][Full Text] [Related]
16. When "Peripheral" Becomes "Central": Primary and Secondary Malignant Intracerebral Nerve Sheath Tumor: A Case Report and a Systematic Review.
Rubino F; Eichberg DG; Shah AH; Luther EM; Lu VM; Saad AG; Kahn D; Komotar RJ; Ivan ME
Neurosurgery; 2021 May; 88(6):1074-1087. PubMed ID: 33647973
[TBL] [Abstract][Full Text] [Related]
17. The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents.
González-Muñoz T; Kim A; Ratner N; Peinado H
Clin Cancer Res; 2022 Aug; 28(15):3185-3195. PubMed ID: 35446392
[TBL] [Abstract][Full Text] [Related]
18. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
20. Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease.
Martin E; Flucke UE; Coert JH; van Noesel MM
Childs Nerv Syst; 2020 Oct; 36(10):2453-2462. PubMed ID: 32494969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
